Loading...
XNAS
NVCR
Market cap1.87bUSD
Apr 03, Last price  
16.98USD
1D
-5.35%
1Q
-43.76%
Jan 2017
116.31%
IPO
-9.15%
Name

Novocure Ltd

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
3.08
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.09%
Rev. gr., 5y
11.49%
Revenues
605m
+18.82%
10,359,00015,490,00033,087,00082,888,000177,026,000248,069,000351,318,000494,366,000535,031,000537,840,000509,338,000605,220,000
Net income
-169m
L-18.55%
-77,370,000-80,682,000-111,581,000-131,845,000-61,662,000-63,559,000-7,230,00019,808,000-58,351,000-92,534,000-207,043,000-168,627,000
CFO
-26m
L-64.04%
-52,717,000-74,244,000-99,884,000-107,592,000-33,134,000-1,865,00026,620,00099,148,00082,756,00030,788,000-73,336,000-26,369,000
Earnings
Jun 05, 2025

Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
URL
https://www.novocure.com/
IPO date
Oct 01, 2015
Employees
1,320
Domiciled in
JE
Incorporated in
JE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
605,220
18.82%
509,338
-5.30%
537,840
0.53%
Cost of revenue
775,716
742,208
627,363
Unusual Expense (Income)
NOPBT
(170,496)
(232,870)
(89,523)
NOPBT Margin
Operating Taxes
37,465
15,303
10,688
Tax Rate
NOPAT
(207,961)
(248,173)
(100,211)
Net income
(168,627)
-18.55%
(207,043)
123.75%
(92,534)
58.58%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,150
4,416
5,224
BB yield
-0.13%
-0.28%
-0.07%
Debt
Debt current
101,053
73,580
Long-term debt
27,894
623,662
603,033
Deferred revenue
2,878
Other long-term liabilities
124,229
8,276
4,552
Net debt
(830,926)
(286,954)
(292,812)
Cash flow
Cash from operating activities
(26,369)
(73,336)
30,788
CAPEX
(42,855)
(27,093)
(21,358)
Cash from investing activities
(140,242)
184,148
(139,957)
Cash from financing activities
90,315
15,787
15,491
FCF
(229,854)
(213,811)
(115,162)
Balance
Cash
959,873
910,616
969,425
Long term investments
Excess cash
929,612
885,149
942,533
Stockholders' equity
(1,159,630)
(990,972)
(780,893)
Invested Capital
1,745,091
1,957,986
1,878,684
ROIC
ROCE
EV
Common stock shares outstanding
107,834
106,391
104,660
Price
29.80
99.60%
14.93
-79.65%
73.35
-2.30%
Market cap
3,213,464
102.31%
1,588,420
-79.31%
7,676,846
-1.15%
EV
2,382,538
1,301,466
7,384,034
EBITDA
(184,905)
(221,901)
(78,899)
EV/EBITDA
Interest
17,327
3,319
3,334
Interest/NOPBT